北京地区氯诺昔康致不良反应48例分析  

Analysis of 48 Cases of Lornoxicam-induced ADR in Beijing

作　　者：崔喜凤[1] 邢丽秋[2] 马超[1] 张树荣[1] 李春钰[1] 

机构地区：[1]北京丰台医院药剂科,北京100071 [2]北京市药品不良反应监测中心,北京100071

出　　处：《中国药房》2015年第32期4523-4525,共3页China Pharmacy

摘　　要：目的：了解氯诺昔康致不良反应发生的特点及一般规律,为临床安全、合理使用氯诺昔康提供参考。方法：查阅国家药品不良反应（ADR）监测系统收集的2006-2013年期间北京地区有关氯诺昔康ADR报告,对其发生的特点及相关因素进行回顾性分析。结果：统计时间内,共收到48份怀疑与氯诺昔康有关的ADR报告。其中,40~59岁年龄段患者居多,占45.83%;38例患者通过静脉滴注或肌内注射使用氯诺昔康注射液,占79.17%;临床表现复杂多样,以皮肤及其附件和胃肠系统损害为多见（各占32.96%、25.00%）。ADR发生在30 min内占35.42%,经停药或对症治疗后1~3 d好转。结论：临床合理使用氯诺昔康可以减少其ADR的发生。建议在使用该药时,对患者进行安全监测,以降低发生ADR的风险。OBJECTIVE： To investigate the characteristics and regularity of lornoxicam related ADR, and to provide reference for rational and safe use of lornoxicam. METHODS： From Jan. 1, 2006 to Dec. 31, 2013, lomoxicam related ADR reports collect- ed by National ADR Monitoring System in Beijing were analyzed retrospectively about their characteristics and related factors. RE- SULTS： In the statistical period, there were 48 ADR reports related to lornoxicam. The people over 40 years age accounted for 62.5%. 38 patients used lomoxicam by intravenous infusion or intramuscular injection , accounting for 79.17%. The clinical mani- festations were diverse and complex, in which skin （32.96%） and gastrointestinal damage （25.00%） were more common ADR oc- curred within 30 min, accounting for 35.42%, and it would be better after stopping drug or 1-3 days symptomatic treatment. CON- CLUSIONS： The rational use of lornoxicam can reduce the occurrence of ADR. Suggestion on the use of the drug, is that the pa- tient should be monitored for security, in order to reduce the risk of ADR.

关 键 词：氯诺昔康 不良反应 影响因素 安全性分析 

分 类 号：R969.3[医药卫生—药理学]